Cargando…

Clinical significance of ≥ 50% PD‐L1 expression with the SP263 monoclonal antibody in non‐small cell lung cancer patients

BACKGROUND: PD‐L1 expression in tumor cells has been associated with the efficacy of immune checkpoint inhibitors in non‐small cell lung cancer (NSCLC). The aim of this study was to explore correlations between smoking, genetic profiles, patient outcomes, and PD‐L1 expression in NSCLC. METHODS: PD‐L...

Descripción completa

Detalles Bibliográficos
Autores principales:	Li, Wenbin, Song, Peng, Guo, Lei, Liu, Xiuyun, Guo, Changyuan, Ying, Jianming, Gao, Shugeng
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley & Sons Australia, Ltd 2018
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6360219/ https://www.ncbi.nlm.nih.gov/pubmed/30536734 http://dx.doi.org/10.1111/1759-7714.12929

Ejemplares similares

Clinicopathologic Correlation With Expression of PD-L1 on Both Tumor Cells and Tumor-infiltrating Immune Cells in Patients With Non–Small Cell Lung Cancer
por: Song, Peng, et al.
Publicado: (2019)

Quantitative and qualitative characterization of Two PD-L1 clones: SP263 and E1L3N
por: Smith, Jacquelyn, et al.
Publicado: (2016)

Correlation between PD-L1 expression (clones 28-8 and SP263) and histopathology in lung adenocarcinoma
por: García, Alejandro, et al.
Publicado: (2020)

PD-L1 expression evaluated by 22C3 antibody is a better prognostic marker than SP142/SP263 antibodies in breast cancer patients after resection
por: Cha, Yoon Jin, et al.
Publicado: (2021)

External quality assessment demonstrates that PD‐L1 22C3 and SP263 assays are systematically different
por: Dodson, Andrew, et al.
Publicado: (2019)

PD-L1 expression comparison between primary and relapsed non-small cell lung carcinoma using whole sections and clone SP263
por: Munari, Enrico, et al.
Publicado: (2018)

CT‐guided transthoracic needle biopsy for evaluation of PD‐L1 expression: Comparison of 22C3 and SP263 assays
por: Beck, Kyongmin S., et al.
Publicado: (2019)

Comprehensive Comparison of 22C3 and SP263 PD-L1 Expression in Non-Small-Cell Lung Cancer Using Routine Clinical and Conditioned Archives
por: Kim, Sue Youn, et al.
Publicado: (2022)

A Comparison of Murine PD-1 and PD-L1 Monoclonal Antibodies
por: Bu, Melissa T., et al.
Publicado: (2022)

SP142 PD-L1 Scoring Shows High Interobserver and Intraobserver Agreement in Triple-negative Breast Carcinoma But Overall Low Percentage Agreement With Other PD-L1 Clones SP263 and 22C3
por: Pang, Jia-Min B., et al.
Publicado: (2021)

Variation of Programmed Death Ligand 1 Expression After Platinum-based Neoadjuvant Chemotherapy in Lung Cancer
por: Guo, Lei, et al.
Publicado: (2019)

Correlation of PD-L1 Expression Tested by 22C3 and SP263 in Non-Small Cell Lung Cancer and Its Prognostic Effect on EGFR Mutation–Positive Lung Adenocarcinoma
por: Kim, Taehee, et al.
Publicado: (2020)

PD-L1 Testing in Gastric Cancer by the Combined Positive Score of the 22C3 PharmDx and SP263 Assay with Clinically Relevant Cut-offs
por: Park, Yujun, et al.
Publicado: (2020)

Intracellular Signaling Transduction Pathways Triggered by a Well-Known Anti-GHR Monoclonal Antibody, Mab263, in Vitro and in Vivo
por: Lan, Hainan, et al.
Publicado: (2014)

The Clinical Significance of Deglycosylated PD-L1 Level Detection Using 28-8 Monoclonal Antibody in Lung Adenocarcinoma
por: Wang, Huiyu, et al.
Publicado: (2022)

Distinct PD-L1 binding characteristics of therapeutic monoclonal antibody durvalumab
por: Tan, Shuguang, et al.
Publicado: (2017)

Immune-related histologic phenotype in pretreatment tumour biopsy predicts the efficacy of neoadjuvant anti-PD-1 treatment in squamous lung cancer
por: Yuan, Pei, et al.
Publicado: (2022)

Comparison of SP263 and 22C3 immunohistochemistry PD-L1 assays for clinical efficacy of adjuvant atezolizumab in non-small cell lung cancer: results from the randomized phase III IMpower010 trial
por: Zhou, Caicun, et al.
Publicado: (2023)

The combination of anti-KIR monoclonal antibodies with anti-PD-1/PD-L1 monoclonal antibodies could be a critical breakthrough in overcoming tumor immune escape in NSCLC
por: He, Yayi, et al.
Publicado: (2018)

Disorder of Coagulation-Fibrinolysis System: An Emerging Toxicity of Anti-PD-1/PD-L1 Monoclonal Antibodies
por: Sato, Ryo, et al.
Publicado: (2019)

Development of canine PD-1/PD-L1 specific monoclonal antibodies and amplification of canine T cell function
por: Choi, Jin Wook, et al.
Publicado: (2020)

Durvalumab: an investigational anti-PD-L1 monoclonal antibody for the treatment of urothelial carcinoma
por: Faiena, Izak, et al.
Publicado: (2018)

Health Tract, No. 263: Experimenting
Publicado: (1867)

Seeing is believing: anti-PD-1/PD-L1 monoclonal antibodies in action for checkpoint blockade tumor immunotherapy
por: Tan, Shuguang, et al.
Publicado: (2016)

Discovery and preclinical characterization of the antagonist anti-PD-L1 monoclonal antibody LY3300054
por: Li, Yiwen, et al.
Publicado: (2018)

A Novel Loss-of-Function Variant in Transmembrane Protein 263 (TMEM263) of Autosomal Dwarfism in Chicken
por: Wu, Zhou, et al.
Publicado: (2018)

An intermediate filament-associated protein, p50, recognized by monoclonal antibodies
Publicado: (1983)

The significance of PD-1/PD-L1 imbalance in ulcerative colitis
por: Shi, Wei, et al.
Publicado: (2023)

PD-L1 expression and the prognostic significance in gastric cancer: a retrospective comparison of three PD-L1 antibody clones (SP142, 28–8 and E1L3N)
por: Ma, Jing, et al.
Publicado: (2018)

Crystal clear: visualizing the intervention mechanism of the PD-1/PD-L1 interaction by two cancer therapeutic monoclonal antibodies
por: Tan, Shuguang, et al.
Publicado: (2016)

Different pathologic responses to neoadjuvant anti-PD-1 in primary squamous lung cancer and regional lymph nodes
por: Ling, Yun, et al.
Publicado: (2020)

Granulomatous myositis induced by anti–PD-1 monoclonal antibodies
por: Uchio, Naohiro, et al.
Publicado: (2018)

Correction to: Discovery and preclinical characterization of the antagonist anti-PD-L1 monoclonal antibody LY3300054
por: Li, Yiwen, et al.
Publicado: (2018)

MET overexpression, gene amplification and relevant clinicopathological features in gastric adenocarcinoma
por: Zhang, Jing, et al.
Publicado: (2016)

Optimism Bias in the Design of Phase III Randomized Control Trials Evaluating PD-1/PD-L1 Targeting Monoclonal Antibodies
por: Al-Showbaki, Laith, et al.
Publicado: (2022)

Identification and Validation of a Novel Signature Based on NK Cell Marker Genes to Predict Prognosis and Immunotherapy Response in Lung Adenocarcinoma by Integrated Analysis of Single-Cell and Bulk RNA-Sequencing
por: Song, Peng, et al.
Publicado: (2022)

PD‐L1 and CD47 co‐expression predicts survival and enlightens future dual‐targeting immunotherapy in non‐small cell lung cancer
por: Yang, Zhenlin, et al.
Publicado: (2021)

Investigation of antibody dependent cellular cytotoxicity as a mechanism of action for a novel anti-PD-L1 monoclonal antibody
por: Boyerinas, Benjamin, et al.
Publicado: (2014)

Immunohistochemical assays incorporating SP142 and 22C3 monoclonal antibodies for detection of PD-L1 expression in NSCLC patients with known status of EGFR and ALK genes
por: Krawczyk, Paweł, et al.
Publicado: (2017)

AB263. Ideas from study on pathological large slices of prostate
por: Qu, Yanchun, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_t1seia4k896d5aobmu0uko7hma